Loading…
for educational and safety purposes
Coluracetam and Noopept both come up in the same conversations; they overlap on Acetylcholine. Coluracetam: Coluracetam has the most distinctive proposed mechanism in the racetam family. Noopept: Noopept is one of the most extensively researched dipeptide nootropics, a proline-containing compound designed as a peptide analog of piracetam with far greater potency by weight.
Coluracetam has the most distinctive proposed mechanism in the racetam family. Rather than acting at a receptor, it was designed to raise the rate at which neurons take up choline, the raw material the brain uses to build acetylcholine. Mitsubishi developed it in Japan in the 1990s as an Alzheimer's candidate, and it was later carried into depression research and through a completed 115-person trial. Readers who use it describe sharper focus and, unusually for a nootropic, changes in visual vividness. The evidence for the mechanism is narrower than the reputation: the choline-uptake effect was shown in animals whose cholinergic neurons had been deliberately lesioned first and not in normal tissue, and an independent group at Pfizer testing the same transporter across four separate methods found no effect at all. That lesion-dependence is itself worth understanding, because it would predict a quieter effect in a healthy brain rather than none. No human trial has yet reported a cognitive result; the 2009 study completed without publishing its outcomes.
Noopept is one of the most extensively researched dipeptide nootropics, a proline-containing compound designed as a peptide analog of piracetam with far greater potency by weight. Its standout quality is neuroprotection; in cellular models it guarded neurons against oxidative and amyloid-related damage more effectively than piracetam or classic antioxidants, while attenuating tau hyperphosphorylation [1][3]. Studied for memory restoration and neuroprotection, it also raises endogenous NGF and BDNF and activates adaptive stress-response pathways.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
mild potentiation
agonist
enhances
Increase, again restricted to lesioned tissue. Reversed the AF64A-induced fall in potassium-evoked ACh release from hippocampal synaptosomes and slices, and restored basal hippocampal ACh by in vivo microdialysis. In mice, only chronic dosing restored hippocampal ACh; acute dosing did nothing.
No inhibition. This is affirmative negative evidence from a direct assay, and it distinguishes coluracetam from donepezil, tacrine and the rest of the cholinesterase-inhibitor class.
strengthens
Proposed positive modulator. Reported to raise the Vmax of high-affinity choline uptake about 1.6-fold and the Bmax of [3H]-hemicholinium-3 binding about 1.7-fold, interpreted as driving more transporter to the synaptic membrane rather than changing transporter affinity. Critically, the effect is reported ONLY in cholinergically lesioned tissue and is absent in normal tissue.
No binding. Neither [3H]-quinuclidinyl benzilate (general muscarinic) nor [3H]-pirenzepine (M1-preferring) binding was affected, so the compound is not a muscarinic ligand.
upregulates
enhances
supports
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Noopept is currently listed by more trusted vendors (3), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.